IL33 and COVID-19: Since the TLR7 pathway is required for recognition of the SARS-CoV-2 genome and production of IFN-I, the IL-33/ST2 axis may suppress innate antiviral immunity and delay viral clearance in COVID-19 patients by reducing IFN-I expression (Figure 4).